Congress funds study of rising pediatric liver cancer, named after teen who died
H.R. 5355 — Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act · Filed by Jim Costa (D-CA) · 13 cosponsors · Introduced Sep 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the federal government to study pediatric liver disease detection and screening, particularly biliary atresia (a bile-duct condition in newborns) and pediatric liver cancer, and to launch a public education campaign about early warning signs and living liver donation. It requires the Government Accountability Office to report on trends in liver-transplant wait-list mortality, the cost-effectiveness of adding a bilirubin screening test to newborn panels, and the effectiveness of the education program—but authorizes no new funding.
Why we flagged it
The bill's core function is to mandate federal study and public education on pediatric liver disease detection and organ donation, with no appropriations or regulatory changes. It is a straightforward public-health information and research directive.
What the text implies
- The bill names a deceased teenager (Ian Kalvinskas, died June 2025) as the namesake. While this is a protective/memorial bill addressing the condition that affected him, it may set a precedent for naming public-health legislation after individual cases, which could create pressure for similar bills for other conditions.
- The bill authorizes no new funding, relying on existing HHS and CDC budgets. This may limit the scope and speed of the education program and GAO studies, potentially reducing real-world impact.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies (if new treatments emerge from research findings); transplant centers and pediatric hospitals (increased referrals and procedures); diagnostic testing companies (if bilirubin screening is adopted)